Clinical Review Criteria  
Preimplantation Genetic Diagnosis (PGD)

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Review Criteria, at Kaiser Permanente’s sole discretion, at any time, with or without notice. Member contracts differ in their benefits. Always consult the patient’s Medical Coverage Agreement or call Kaiser Permanente Customer Service to determine coverage for a specific medical service.

Criteria  
For Non-Medicare Members

Preimplantation genetic diagnosis (PGD) is performed on single cells removed from an embryo. Standard prenatal diagnosis is customarily performed on multiple cells obtained by chorionic villous sampling (CVS) or amniocentesis. PGD on single, embryonic cells is considered medically necessary only when there is a need to diagnose a specific, detectable single gene mutation in an embryo at risk due to an identified deleterious genetic mutation in one or both genetic parents, as defined below:

I. In order to meet medically necessary criteria for PGD, both A and B must be met:
   A. There must be documentation confirming that PGD is medically necessary to detect a single gene disorder or chromosomal abnormality whose expression in the fetus or child would be expected to have a significant adverse medical impact and that detection in the pre-implantation period would directly affect reproductive decisions.
   B. One of the following clinical circumstances must be documented:
      1. One genetic parent has a balanced, reciprocal translocation or Robertsonian translocation
      2. One genetic parent has a single gene autosomal dominant disorder
      3. Both genetic parents are known carriers of the same single gene autosomal recessive disorder
      4. The female genetic parent is a known carrier of a single gene X-linked recessive disorder

The procedure to obtain a cell sample from an embryo for PGD is covered when the above criteria for PGD are met. However, the procedures and services (such as IVF) required to create the embryos to be tested and the transfer of embryos to the uterus after testing, are covered only for members with advanced reproductive technology (ART) benefits and who meet medical necessity criteria for IVF (in vitro fertilization).

II. The following are not covered for preimplantation screening:
   A. Aneuploidy screening, including in the setting of recurrent miscarriage or repeated failure of IVF (e.g. screening for Down Syndrome, in women over the age of 35)
   B. Screening for chromosomal abnormalities in the absence of a known, clinically significant genetic or chromosomal defect in a genetic parent
   C. Selecting against conditions or disorders in the absence of a known and identifiable genetic or chromosomal defect in a genetic parent
   D. Gender selection of selection of nonmedical trait to determine an embryo’s carrier status
   E. Screening for autosomal recessive disorders when the embryos are created using donor egg or sperm
   F. Detecting genetic or chromosomal abnormalities contributed by donor egg or sperm
   G. Screening for adult-onset disorders or for genetic predisposition to adult-onset disease
   H. HLA typing of an embryo to identify a future suitable stem cell, tissue or organ transplantation donor.

The following information was used in the development of this document and is provided as background only. It is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

Background

Historically, couples at high risk of transmission of a genetic disorder have had limited reproductive options, forced after prenatal diagnosis to choose between either termination of affected pregnancies or acceptance of the emotional and financial burden of having a child with severe disability and early mortality. Preimplantation genetic diagnosis (PGD) was introduced to enhance efficiency in assisted conception. It is a technique for reducing the burden of genetic disease performed on couples who are at risk of a specific inherited disorder and used to
identify genetic defects present in embryos created through in vitro fertilization (IVF) before transferring them to the uterus.

PGD is performed in conjunction with IVF and is offered to both fertile and infertile couples. Introduced in 1990 as an experimental procedure, PGD has now become an established clinical option in reproductive medicine (Handyside, Kontogianni et al. 1990; Verlinsky, Ginsberg et al. 1990). Because only unaffected embryos are transferred to the uterus for implantation, PGD can provide an alternative to current postconception diagnostic procedures such as amniocentesis or chorionic villus sampling which are sometimes followed by pregnancy termination when results are unfavorable (Verlinsky, Cohen et al. 2004). PGD techniques are now also being utilized for preimplantation genetic screening (PGS) with the intent to identify potential genetic abnormalities in conjunction with IVF for couples without specific known inherited disorders.

With single gene disorders and inherited chromosomal abnormalities being the main indicators for PGD, the technique is available for most known genetic mutations. With that said, PGD can be considered a rapidly evolving technique. Put simply, PGD requires egg extraction, IVF, cell biopsy, genetic analysis and embryo transfer (Handyside, Kontogianni et al. 1990). At present, there are three different procedures utilized for cell biopsy, each with its own advantages and disadvantages, including polar body biopsy, cleavage-stage embryo biopsy and blastocyst biopsy. Depending on the whether the characteristic being tested for is associated with chromosomes or DNA, the sample can be analyzed in one of three ways including polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) and comparative genomic hybridization with new technologies emerging rapidly. Regardless of the methods, the results are used by parents and providers to select which embryos are transferred back to the uterus with the ultimate goal of establishing an unaffected pregnancy.

The accuracy and reliability of PGD are key issues and exploring these matters requires consideration of the technical challenges and risks inherent in the genetic test itself and in the IVF procedure that it entails. Any PGD strategy has to deal with the detection and avoidance of misdiagnosis from the onset with the risk and outcome relating directly to the type of genetic disorder for which testing is performed. Although PGD has been suggested as an alternative for current post conception diagnostic procedures, the amount of DNA available for testing is limited. Due to this risk, prenatal diagnosis by amniocentesis or chronic villus sampling testing is strongly recommended upon established pregnancy to confirm genetic health.

<table>
<thead>
<tr>
<th>Date Created</th>
<th>Date Reviewed</th>
<th>Date Last Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/03/2013</td>
<td>12/03/2013 MPC, 10/07/2014 MPC, 08/04/2015 MPC, 06/07/2016 MPC, 04/04/2017 MPC</td>
<td>12/03/2013</td>
</tr>
</tbody>
</table>

MPC Medical Policy Committee

<table>
<thead>
<tr>
<th>Revision History</th>
<th>Description</th>
</tr>
</thead>
</table>

Codes
CPT: 89290; 89291